FATE,Fate Therapeutics, Inc. | Healthcare

Healthcare

FATE

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Fate Therapeutics, Inc.FATE

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors.

The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer.

Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Latest News >

Gold prices today: Yellow metal gains as government hikes import duty

Jul 1, 2022

The government, on Friday, hiked gold import duty to curb import. The basic customs duty on gold has been increased from 10.75 percent to 15 percent to decrease current account deficit (CAD).

Stock Market Highlights: Sensex ends 111 pts lower and Nifty50 near 15,750 — rupee sinks below 79 for first time

Jun 30, 2022

Stock Market Highlights: Indian equity benchmarks BSE Sensex and NSE Nifty50 finished a choppy session in the red on Friday as losses in oil & gas shares outweighed gains in financial, IT and FMCG stocks. The rupee closed below the 79 mark against the US dollar for the first time. Broader markets, however, managed to make it to the green, closing with gains of around half a percent each. Nervousness persisted among investors globally amid fears aggressive hikes in COVID-era interest rates will hamper economic growth.

Editors’ Roundtable: The week gone by

Jul 1, 2022

CNBC-TV18’s brand new offering, the ‘Editor’s Roundtable’ brings the latest happenings of the week gone by, the big trends to watch, sharp insights and in-depth analyses from the CNBC-TV18 Editors.

Bajaj Finance closes 3% higher as investors opt for bargain buying

Jul 1, 2022

Bajaj Finance shares: The stock closed 3.97 percent higher at Rs 5,614.8 on the BSE. With today's gains, the stock has snapped a three-day losing streak.